JPWO2021202926A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021202926A5 JPWO2021202926A5 JP2022560454A JP2022560454A JPWO2021202926A5 JP WO2021202926 A5 JPWO2021202926 A5 JP WO2021202926A5 JP 2022560454 A JP2022560454 A JP 2022560454A JP 2022560454 A JP2022560454 A JP 2022560454A JP WO2021202926 A5 JPWO2021202926 A5 JP WO2021202926A5
- Authority
- JP
- Japan
- Prior art keywords
- binds
- molecule
- antigen
- binding domain
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims description 92
- 102000036639 antigens Human genes 0.000 claims description 92
- 108091007433 antigens Proteins 0.000 claims description 92
- 230000000694 effects Effects 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 47
- 102000008166 Member 25 Tumor Necrosis Factor Receptors Human genes 0.000 claims description 46
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 46
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 44
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 claims description 12
- 230000004927 fusion Effects 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 230000001603 reducing effect Effects 0.000 claims description 12
- 201000004624 Dermatitis Diseases 0.000 claims description 10
- 208000023504 respiratory system disease Diseases 0.000 claims description 10
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000003176 fibrotic effect Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 239000000816 peptidomimetic Substances 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 claims description 6
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 4
- 206010014568 Empyema Diseases 0.000 claims description 4
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 claims description 4
- 206010006451 bronchitis Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 230000000670 limiting effect Effects 0.000 claims description 4
- 208000008423 pleurisy Diseases 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000000884 Airway Obstruction Diseases 0.000 claims description 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims description 2
- 206010003598 Atelectasis Diseases 0.000 claims description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 2
- 206010004485 Berylliosis Diseases 0.000 claims description 2
- 206010006448 Bronchiolitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010014950 Eosinophilia Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 208000000616 Hemoptysis Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000003892 Kartagener syndrome Diseases 0.000 claims description 2
- 208000002260 Keloid Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 206010059033 Neonatal aspiration Diseases 0.000 claims description 2
- 208000002151 Pleural effusion Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000007123 Pulmonary Atelectasis Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000001941 Scleromyxedema Diseases 0.000 claims description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 208000008784 apnea Diseases 0.000 claims description 2
- 206010003441 asbestosis Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 201000009805 cryptogenic organizing pneumonia Diseases 0.000 claims description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 claims description 2
- 230000004761 fibrosis Effects 0.000 claims description 2
- 201000005298 gastrointestinal allergy Diseases 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
- 230000001861 immunosuppressant effect Effects 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000001503 joint Anatomy 0.000 claims description 2
- 210000001117 keloid Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 230000002988 nephrogenic effect Effects 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 201000003144 pneumothorax Diseases 0.000 claims description 2
- 201000009266 primary ciliary dyskinesia Diseases 0.000 claims description 2
- 206010051951 scimitar syndrome Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 230000008961 swelling Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 208000006601 tracheal stenosis Diseases 0.000 claims description 2
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims 7
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 4
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004030P | 2020-04-02 | 2020-04-02 | |
| US63/004,030 | 2020-04-02 | ||
| PCT/US2021/025453 WO2021202926A1 (en) | 2020-04-02 | 2021-04-01 | Methods and combinations for dual targeting of tnf family members |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023530046A JP2023530046A (ja) | 2023-07-13 |
| JPWO2021202926A5 true JPWO2021202926A5 (de) | 2024-04-10 |
Family
ID=77928094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022560454A Pending JP2023530046A (ja) | 2020-04-02 | 2021-04-01 | Ｔｎｆファミリーのメンバーの二重標的化のための方法および組合せ |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230159649A1 (de) |
| EP (1) | EP4126960A1 (de) |
| JP (1) | JP2023530046A (de) |
| WO (1) | WO2021202926A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024173865A2 (en) * | 2023-02-17 | 2024-08-22 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the kidney |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090317388A1 (en) * | 2005-05-25 | 2009-12-24 | Linda Burkly | Tl1a in treatment of disease |
| EP3750554A3 (de) * | 2007-09-18 | 2021-07-28 | La Jolla Institute for Allergy and Immunology | Light-inhibitoren zur behandlung von asthma, lungen- und atemwegsentzündungen sowie respiratorischen, interstitiellen, pulmonaren und fibrotischen krankheiten |
| EP2978440B1 (de) * | 2013-03-27 | 2019-10-02 | Cedars-Sinai Medical Center | Behandlung von fibrose durch tl1a-hemmung und diagnose von fibrose durch il31ra-nachweis |
| WO2016127059A2 (en) * | 2015-02-05 | 2016-08-11 | La Jolla Institute For Allergy And Immunology | Light inhibitors for scleroderma and skin fibrotic disease treatment |
| CR20180365A (es) * | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
-
2021
- 2021-04-01 JP JP2022560454A patent/JP2023530046A/ja active Pending
- 2021-04-01 EP EP21780761.9A patent/EP4126960A1/de active Pending
- 2021-04-01 US US17/916,548 patent/US20230159649A1/en active Pending
- 2021-04-01 WO PCT/US2021/025453 patent/WO2021202926A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI759261B (zh) | Ｉｌ－６受體抗體用於製備醫藥組成物的用途 | |
| RU2427589C2 (ru) | Антитела против интерлейкина-13 человека и их применение | |
| JP2020503362A5 (de) | ||
| RU2434881C2 (ru) | Il-13 связывающие агенты | |
| JP5904552B2 (ja) | 膵癌治療剤 | |
| JP2008511542A5 (de) | ||
| US20170081412A1 (en) | Antibody-fynomer conjugates | |
| JP2023080215A (ja) | 肝細胞癌のための免疫療法 | |
| JP2008502366A5 (de) | ||
| JP2017533705A (ja) | 抗ｔｎｆ−／抗ｉｌ−２３二重特異性抗体 | |
| RU2754760C2 (ru) | Водная фармацевтическая композиция анти-il17a антитела и ее применение | |
| JP2011516041A5 (de) | ||
| JP7458790B2 (ja) | Ｉｌ－６阻害剤を含有する喘息の治療剤 | |
| JP2020504135A5 (de) | ||
| JPWO2021202926A5 (de) | ||
| TW202124434A (zh) | 抗-幹細胞因子抗體及其使用方法 | |
| WO2018139404A1 (ja) | 放射線障害の治療又は予防剤並びに治療又は予防方法 | |
| TW202214287A (zh) | TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途 | |
| JPWO2019228514A5 (de) | ||
| WO2023020624A1 (en) | Use of alpha-enolase antagonist in treating fibrotic diseases | |
| US11530266B2 (en) | Anti-podoplanin antibody | |
| US20220033486A1 (en) | Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma | |
| WO2024057232A1 (en) | Antibodies, compositions, and methods of treatment | |
| CN117467011A (zh) | 一种抗FcRn抗体及其制剂与应用 | |
| JPWO2022034044A5 (de) |